BioReg­num: The mob is back. And what's to stop them from go­ing af­ter the en­tire bio­phar­ma in­dus­try?

My­lan to­day is at the cen­ter of the lat­est on­line mael­strom to erupt over drug pric­ing and ac­cess to ther­a­pies. And while it hun­kers down to see if it can wait out the storm that has erupt­ed over the EpiPen, the one man who can do it the most dam­age is rid­ing to its res­cue.

En­ter Mar­tin Shkre­li, for­mer biotech CEO and the most wide­ly hat­ed in­di­vid­ual in bio­phar­ma his­to­ry. Shkre­li spe­cial­ized in taunt­ing the dig­i­tal lynch mob that formed af­ter he raised the price of an an­cient drug called dara­prim by more than 5000% af­ter snatch­ing it up for a song. And he kept the crowd stirred by reneg­ing on a promise to roll back the price.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.